Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients

Neurotrophic tyrosine receptor kinase gene fusions (<i>NTRK</i>) are oncogenic drivers present at a low frequency in most tumour types (<5%), and at a higher frequency (>80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and considered mutually exclusive with other common on...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sébastien Perreault, Rose Chami, Rebecca J. Deyell, Dina El Demellawy, Benjamin Ellezam, Nada Jabado, Daniel A. Morgenstern, Aru Narendran, Poul H. B. Sorensen, Jonathan D. Wasserman, Stephen Yip
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-01-01
Colecção:	Current Oncology
Assuntos:	<i>NTRK</i> larotrectinib entrectinib targeted therapy molecular testing oncogenic drivers
Acesso em linha:	https://www.mdpi.com/1718-7729/28/1/38
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!